KOSDAQElectrical Equipment048870

Synergy Innovation

₩1,194▼ 1.65%2026-11-18 close
Market Cap
₩105.2B
Turnover
₩400M
Volume
360K
Shares out.
88.1M
PER
—
PBR
0.5×
EPS
-₩33
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating profit grew, but quarterly net losses are the swing factor

Synergy Innovation's operating profit has risen for three consecutive years through 2025, yet net income attributable to controlling shareholders fell 71.0% in 2025 and swung to a KRW 8.95 billion net loss in the third quarter of 2026, so earnings durability and the outcome of a subsidiary stake sale are the next items to track.

  1. 1

    2025 revenue reached KRW 113.1 billion, up 24.8% year on year, and operating profit reached KRW 19.2 billion, up 19.0%.

  2. 2

    Net income attributable to controlling shareholders fell 71.0% to KRW 3.01 billion in 2025, a wide gap from net income of KRW 11.2 billion including non-controlling interests.

  3. 3

    Third-quarter 2026 operating profit stayed positive at KRW 4.32 billion, but the controlling-shareholder net loss was KRW 8.95 billion. The cumulative net loss over the last four quarters is KRW 2.77 billion.

  4. 4

    The buyer did not pay the balance of the 25% stake in a subsidiary by November 12, 2026, which gave rise to a contract termination ground, according to a November 13, 2026 correction filing. The long-stop date for closing is November 30, 2026.

  5. 5

    At the end of 2025 the debt ratio stood at 23.7%, with total equity of KRW 272.4 billion, of which KRW 211.5 billion belonged to controlling shareholders, and total liabilities of KRW 64.5 billion.

02

Business structure

Synergy Innovation is a mid-sized bio company that runs medical, in-vitro diagnostics, environmental monitoring and health functional food businesses on a bio-technology base. Its operations split into two main segments: medical and bio-technology.

The medical segment sells non-vascular and vascular stents, and the non-vascular stent market is described as growing on the back of a preference for minimally invasive procedures (FnGuide). According to Wisereport, 92.29% of non-vascular stent sales in 2025 were exports.

The bio-technology segment centers on culture media for diagnostics and environmental monitoring products, produced under ISO 13485 and KGMP certified conditions. Its main customers are hospitals, research institutes and bio companies.

R&D spending in 2025 was KRW 7.64 billion, or 6.76% of revenue (Wisereport, consolidated basis). Overseas sales expansion at key subsidiaries was disclosed as the main driver of the 2025 revenue and operating profit increase (Nate News, March 12, 2026).

In new drugs, a subsidiary develops drugs for brain and central nervous system diseases and remains in R&D. Since 2024 the company has invested in production facility expansion and automation.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩30.4B₩6.4B21.0%
2025Q4₩27.8B₩3.3B11.9%
2026Q1₩27B₩3.8B14.1%
2026Q2₩31.4B₩5.4B17.1%
2026Q3₩29.3B₩4.3B14.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩30.3B₩1.2B₩16.1B4.0%11.5%32.5%
2023₩83.2B₩15B₩2.3B18.0%1.3%28.4%
2024₩90.6B₩16.1B₩10.4B17.8%5.7%33.6%
2025₩113.1B₩19.2B₩3B17.0%1.4%23.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On an annual basis, revenue rose from KRW 30.3 billion in 2022 to KRW 83.2 billion in 2023, up 174.5% year on year, and then grew for three consecutive years to KRW 90.6 billion in 2024 (up 8.9%) and KRW 113.1 billion in 2025 (up 24.8%).

Operating profit jumped from KRW 1.2 billion in 2022 to KRW 15 billion in 2023, up 1,144.7%, and then rose for three consecutive years to KRW 16.1 billion in 2024 and KRW 19.2 billion in 2025. The operating margin climbed from 4.0% in 2022 to 18.0% in 2023 and then held near 17% at 17.8% in 2024 and 17.0% in 2025.

In 2025 revenue grew 24.8% while operating profit grew 19.0%, so the margin edged lower.

Net income attributable to controlling shareholders moved from KRW 16.1 billion in 2022 to KRW 2.3 billion in 2023 (down 85.7%), KRW 10.4 billion in 2024 (up 350.0%) and KRW 3.01 billion in 2025 (down 71.0%), with 2022 the largest year in the period.

Net income including non-controlling interests was KRW 22.8 billion in 2022, KRW 7.55 billion in 2023, KRW 18.1 billion in 2024 and KRW 11.2 billion in 2025. The 2025 decline in net income was attributed to losses from valuation of derivatives and investment assets (Nate News).

Operating cash flow was KRW 12.9 billion in 2022, KRW 35.4 billion in 2023, KRW 26.5 billion in 2024 and KRW 14.8 billion in 2025. The debt ratio went from 32.5% in 2022 to 28.4% in 2023, 33.6% in 2024 and 23.7% in 2025.

Quarterly revenue peaked at KRW 30.4 billion in the third quarter of 2025, fell to KRW 27.8 billion in the fourth quarter (down 8.6% quarter on quarter) and KRW 27 billion in the first quarter of 2026, then rebounded to KRW 31.4 billion in the second quarter (up 16.2%) before reaching KRW 29.3 billion in the third quarter, down 3.7% year on year.

Operating profit went from KRW 6.37 billion in the third quarter of 2025 to KRW 3.31 billion in the fourth quarter, recovered to KRW 5.38 billion in the second quarter of 2026, and in the third quarter of 2026 was KRW 4.32 billion, down 32.2% year on year, a steeper decline than the 3.7% revenue decline.

Controlling-shareholder net income moved to a KRW 2.9 billion loss in the fourth quarter of 2025, back to a KRW 3.85 billion profit in the first quarter of 2026, KRW 5.23 billion in the second quarter, and a KRW 8.95 billion loss in the third quarter of 2026.

With operating profit still positive while controlling-shareholder earnings turned to a loss, the composition of non-operating items is the point to watch in coming quarters.

05

Industry analysis

Market data providers classify Synergy Innovation under the KOSDAQ medical and precision instruments sector (Wisereport). The medical equipment and supplies industry is used as the comparison group, in line with the business mix.

In a 2025 year-end comparison compiled by AlphaSquare, the company ranked 13th of 97 companies in the medical equipment and supplies industry on operating profit and 14th on operating margin. On demand, a shift toward minimally invasive procedures and an aging population are cited as drivers for non-vascular stents.

In diagnostics and environmental monitoring, the prevailing brokerage view is that demand for these products has remained steady. Securities analysts generally describe the company as being in a phase of structural improvement rather than judging it on near-term earnings (Pinpoint News).

On supply, the company has invested since 2024 in facility expansion and production automation, with capacity expected to rise about 13%, and productivity gains were expected after the first half of 2025 (Wisereport).

Because exports are a large share of stent sales, the business is exposed to overseas demand and changes in certification and regulation across countries.

On competition, ISO 13485 and KGMP certification is described as a trust factor in expanding deals with domestic and foreign diagnostics, pharmaceutical and bio companies. In new drugs, an aging population is expanding the market for degenerative brain diseases, but the pipeline remains in R&D.

06

Outlook

No company earnings guidance was confirmed for the coming period, so the outlook rests on disclosures and dated events. The nearest fact is the sale of a 25% stake in a subsidiary for about KRW 44.98 billion, equal to 16.51% of equity.

The buyer missed the balance due by November 12, 2026, which gave rise to a contract termination ground. The final closing deadline is November 30, 2026, and the company said it will disclose promptly once the termination decision is made (Global Economic, November 13, 2026).

The result will change the subsidiary's ownership structure and the timing of cash inflows. The largest shareholder pledged 2,132,764 shares (2.42%) under a share pledge contract running through November 18, 2026 (Digital Today, report dated May 21, 2026).

On capital policy, the company said it would cancel in full bonds worth KRW 4.55 billion acquired through a call option on its 14th convertible bond issue, with cancellation scheduled for June 9, 2026 (News1). The company described this as eliminating a potential dilution factor and enhancing shareholder value.

The same bond's conversion price was lowered on April 22, 2026, following a decline in the share price (GoInsider). The new-drug pipeline is at a stage where technology transfer or clinical progress is discussed, with no dated milestone confirmed.

The next periodic report is the 2026 annual report, which based on last year's filing date of March 19, 2026, is likely around March 2027, when the fourth-quarter 2026 results and full-year operating margin and controlling-shareholder net income trend will be confirmed.

07

Valuation

PER
—
PBR
0.5×
ROE
-1.3%
EPS
-₩33
BPS
₩2,428
Dividend per share
₩0

Because the controlling-shareholder net loss has continued over the last four quarters, the price-to-earnings ratio cannot be calculated. Earnings-based multiples therefore offer no comparison, and book-value measures are the more usual reference.

The price-to-book ratio sits below 1x, meaning the shares trade under the book value per share. Against controlling-shareholder equity of KRW 211.5 billion at the end of 2025, market value is recorded at a discount to net assets.

The dividend yield is below the industry average, so shareholder returns have leaned on capital measures such as share cancellation and convertible bond clean-up.

Revenue and operating profit have risen since 2022, yet controlling-shareholder net income has swung widely, so any multiple-based comparison depends heavily on which earnings direction is assumed.

The convertible bond conversion price was lowered after the share price fell, so dilution is a factor to keep in view alongside the capital structure. Read this way, the valuation rests on a comparison of book value with earnings recovery rather than on any single multiple.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Sustained operating profitability

Operating profit has risen for three consecutive years since 2023, and the operating margin held in the 17% range at 18.0% in 2023, 17.8% in 2024 and 17.0% in 2025. Holding the margin after a sharp improvement from 4.0% in 2022 is read as evidence the core earnings structure has settled. Second-quarter 2026 operating profit of KRW 5.38 billion was the second highest among the quarters shown.

Financial capacity and low leverage

The debt ratio at the end of 2025 was 23.7%, the lowest since 2022, with total liabilities of KRW 64.5 billion and total equity of KRW 272.4 billion. Operating cash flow stayed positive at KRW 14.8 billion in 2025.

A solid balance sheet allows the company to pursue subsidiary stake sales alongside investment in its businesses.

Export base and capacity expansion

In 2025, 92.29% of non-vascular stent sales were exports, so an overseas sales base is already in place. Facility expansion and automation began in 2024, with capacity planned to rise about 13%. Overseas sales expansion was disclosed as the main driver of the 2025 revenue and operating profit increase.

09

Bear factors

Swing to a controlling-shareholder loss

The controlling-shareholder net loss in the third quarter of 2026 was KRW 8.95 billion, and the cumulative loss over the last four quarters is KRW 2.77 billion. Operating profit stayed positive over the same period, which points to non-operating items pulling down the bottom line.

Whether the causes are one-off or recurring can only be confirmed through later disclosures, and the P/E ratio cannot currently be calculated.

Frequent reversals in earnings direction

Net income attributable to controlling shareholders went from KRW 16.1 billion in 2022 to KRW 2.3 billion in 2023 (down 85.7%), KRW 10.4 billion in 2024 (up 350.0%) and KRW 3.01 billion in 2025 (down 71.0%). Net income in 2025 fell after valuation losses on derivatives and investment assets were reflected.

Even with rising operating profit, the controlling share can move sharply depending on valuation gains and losses and the non-controlling structure.

Share pledge and subsidiary deal uncertainty

The largest shareholder pledged 2.42% of its stake under a contract that runs through November 18, 2026. The 25% subsidiary stake sale in a subsidiary gave rise to a contract termination ground after the buyer missed the balance, with the closing deadline set for November 30, 2026. If the deal falls through, expected cash inflows and the restructuring of the ownership would be delayed.

10

Risk factors

Subsidiary stake transaction

The sale of a 25% stake in a subsidiary has a total value of about KRW 44.98 billion, equal to 16.51% of equity, after the buyer missed the balance. The outcome would materially change the balance sheet and the subsidiary's ownership structure. The termination decision is expected to be disclosed around the November 30, 2026 closing deadline.

Earnings volatility and valuation gains and losses

Net income in 2025 was affected by valuation losses on derivatives and investment assets, and controlling-shareholder net income varied sharply from year to year. Even with positive operating profit, controlling-shareholder earnings can turn negative because of valuation gains and losses and non-operating items.

Assessing earnings quality requires tracking the gap between operating profit and controlling-shareholder net income each quarter.

Export dependence and R&D burden

In 2025, 92.29% of non-vascular stent sales were exports, which exposes the business to overseas demand and changes in certification and regulation in each country. R&D spending in 2025 was KRW 7.64 billion, or 6.76% of revenue. The new-drug pipeline remains in R&D, so its cost burden may continue to weigh on earnings.

11

What to watch next

  1. November 18, 2026

    The end date of the share pledge covering 2.42% held by the largest shareholder side. Whether the contract is extended or released will appear in disclosures and indicates the stability of the shareholding.

  2. November 30, 2026

    The final closing deadline for the sale of a 25% stake in a subsidiary. The termination decision and settlement of the balance will be disclosed, fixing the subsequent ownership structure and the size of cash inflows.

  3. Early March 2027

    The 2026 full-year results disclosure is expected. This is an estimate based on the precedent that last year's full-year revenue and profit change disclosure came on March 12, 2026, and it is the first point to confirm the 2026 annual operating margin and direction of controlling-shareholder net income.

  4. Mid-March 2027

    The 2026 annual report is due for filing. This is an estimate based on last year's filing date of March 19, 2026, and it is the periodic report that first confirms fourth-quarter 2026 results and the finalized annual financial statements.

12

Overall view

Synergy Innovation's operating profit has risen for three consecutive years since 2023, and the operating margin has held in the 17% range, showing a pattern of expanding core revenue and margins.

On the other side, net income attributable to controlling shareholders fell 71.0% to KRW 3.01 billion in 2025 and turned into a KRW 8.95 billion loss in the third quarter of 2026.

The cumulative controlling-shareholder net loss over the last four quarters is KRW 2.77 billion, while operating profit stayed positive over the same period. Financially, the debt ratio at the end of 2025 was 23.7% with total equity of KRW 272.4 billion, so leverage is relatively light.

On valuation, the P/E ratio cannot be calculated and the price-to-book ratio sits below 1x. The next checkpoints are the November 18, 2026 end of the share pledge, the November 30, 2026 closing deadline for the subsidiary stake sale, and the 2026 full-year results and annual report in March 2027.

Operating capacity has been maintained, but the direction of controlling-shareholder earnings and the outcome of the subsidiary stake sale are the most important variables.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. alphasquare.co.kr
  3. comp.wisereport.co.kr
  4. pinpointnews.co.kr
  5. comp.wisereport.co.kr
  6. m.news.nate.com
  7. goinsider.kr
  8. v.daum.net
  9. ssl.pstatic.net
  10. seo.goover.ai
  11. m.news.nate.com
  12. m.news.nate.com
  13. digitaltoday.co.kr
  14. news.nate.com
  15. g-enews.com
  16. m.news.nate.com
  17. m.news.nate.com
  18. stockinfo7.com

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis